FATE THERAPEUTICS INC Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
FATE THERAPEUTICS INC (FATE) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 39.13 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-13
- FATE THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 39.23M shares, a 15.28% increase year-over-year.
- FATE THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 34.03M shares, a 11.26% increase year-over-year.
- FATE THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 30.58M shares, a 2.57% increase year-over-year.
- FATE THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2023-09-30 was 27.50M shares, a 0.73% increase year-over-year.
- FATE THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 32.81M shares, a 6.84% increase from fiscal 2024.
- FATE THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 30.71M shares, a 14.93% increase from fiscal 2023.
- FATE THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 26.72M shares, a 1.41% decline from fiscal 2022.
- FATE THERAPEUTICS INC antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 27.10M shares, a 5.50% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 39.13M shares 10-Q · filed 2026-08-13 | |||||||
| 2026-03-31 | 39.23M shares 10-Q · filed 2026-05-13 | |||||||
| 2025-12-31 | 32.81M shares 10-K · filed 2026-02-26 | |||||||
| 2025-09-30 | 33.02M shares 10-Q · filed 2025-11-13 | |||||||
| 2025-06-30 | 33.52M shares 10-Q · filed 2026-08-13 | |||||||
| 2025-03-31 | 34.03M shares 10-Q · filed 2026-05-13 | |||||||
| 2024-12-31 | 30.71M shares 10-K · filed 2026-02-26 | |||||||
| 2024-09-30 | 31.25M shares 10-Q · filed 2025-11-13 | |||||||
| 2024-06-30 | 29.64M shares 10-Q · filed 2025-08-12 | |||||||
| 2024-03-31 | 30.58M shares 10-Q · filed 2025-05-13 | |||||||
| 2023-12-31 | 26.72M shares 10-K · filed 2025-03-05 | |||||||
| 2023-09-30 | 27.50M shares 10-Q · filed 2023-11-08 | 27.51M shares 10-Q · filed 2024-11-12 | 27.50M shares 10-Q · filed 2023-11-08 | |||||
| 2023-06-30 | 29.10M shares 10-Q · filed 2023-08-08 | 29.08M shares 10-Q · filed 2024-08-13 | 29.10M shares 10-Q · filed 2023-08-08 | |||||
| 2023-03-31 | 29.82M shares 10-Q · filed 2024-05-09 | 29.80M shares 10-Q · filed 2023-05-03 | ||||||
| 2022-12-31 | 27.10M shares 10-K · filed 2024-02-26 | |||||||
| 2022-09-30 | 27.30M shares 10-Q · filed 2023-11-08 | 27.30M shares 10-Q · filed 2023-11-08 | ||||||
| 2022-06-30 | 27.70M shares 10-Q · filed 2023-08-08 | 27.70M shares 10-Q · filed 2023-08-08 | ||||||
| 2022-03-31 | 27.70M shares 10-Q · filed 2023-05-03 | |||||||
| 2021-12-31 | 25.69M shares 10-K · filed 2023-02-28 | |||||||
| 2021-09-30 | 23.90M shares 10-Q · filed 2021-11-04 | 23.90M shares 10-Q · filed 2021-11-04 | ||||||
| 2021-06-30 | 25.10M shares 10-Q · filed 2022-08-03 | 25.10M shares 10-Q · filed 2022-08-03 | ||||||
| 2021-03-31 | 25.50M shares 10-Q · filed 2022-05-04 | |||||||
| 2020-12-31 | 25.81M shares 10-K · filed 2023-02-28 | |||||||
| 2020-09-30 | 26.10M shares 10-Q · filed 2021-11-04 | 26.10M shares 10-Q · filed 2021-11-04 | ||||||
| 2020-06-30 | 25.80M shares 10-Q · filed 2021-08-04 | 25.80M shares 10-Q · filed 2021-08-04 | ||||||
| 2020-03-31 | 25.90M shares 10-Q · filed 2021-05-05 | |||||||
| 2019-12-31 | 23.82M shares 10-K · filed 2022-02-28 | |||||||
| 2019-09-30 | 24.00M shares 10-Q · filed 2020-11-05 | 24.00M shares 10-Q · filed 2020-11-05 | ||||||
| 2019-06-30 | 24.10M shares 10-Q · filed 2020-08-05 | 24.10M shares 10-Q · filed 2020-08-05 | ||||||
| 2019-03-31 | 23.90M shares 10-Q · filed 2020-05-11 | |||||||
| 2018-12-31 | 21.35M shares 10-K · filed 2021-02-24 | |||||||
| 2017-12-31 | 19.99M shares 10-K · filed 2020-03-02 | |||||||
| 2016-12-31 | 18.67M shares 10-K · filed 2019-03-05 | |||||||
| 2015-12-31 | 3.25M shares 10-K · filed 2018-03-05 | 2.72M shares 10-K · filed 2016-03-03 | ||||||
| 2014-12-31 | 2.56M shares 10-K · filed 2017-03-16 | |||||||
| 2013-12-31 | 1.76M shares 10-K · filed 2016-03-03 | |||||||
| 2013-09-30 | 9.46M shares 10-Q · filed 2013-11-13 | 9.46M shares 10-Q · filed 2013-11-13 | ||||||
| 2012-12-31 | 9.10M shares 10-K · filed 2015-03-12 | |||||||
| 2012-09-30 | 7.23M shares 10-Q · filed 2013-11-13 | 7.23M shares 10-Q · filed 2013-11-13 | ||||||
| 2011-12-31 | 6.07M shares 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |